Janux Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 69

Employees

  • Stock Symbol
  • JANX

Stock Symbol

  • Share Price
  • $52.03
  • (As of Wednesday Closing)

Janux Therapeutics General Information

Description

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Contact Information

Website
www.januxrx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • La Jolla, CA 92037
  • United States
+1 (858)

Janux Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Janux Therapeutics Stock Performance

As of 13-Nov-2024, Janux Therapeutics’s stock price is $52.03. Its current market cap is $2.73B with 52.5M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$52.03 $52.84 $7.79 - $65.60 $2.73B 52.5M 597K -$1.17

Janux Therapeutics Financials Summary

As of 30-Sep-2024, Janux Therapeutics has a trailing 12-month revenue of $13M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,747,360 170,386 234,034 433,723
Revenue 13,049 8,083 8,612 3,637
EBITDA (83,883) (71,024) (66,250) (32,816)
Net Income (60,536) (58,293) (63,059) (32,672)
Total Assets 695,019 380,407 364,010 379,824
Total Debt 23,431 24,542 25,305 194
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Janux Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Janux Therapeutics‘s full profile, request access.

Request a free trial

Janux Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Janux Therapeutics‘s full profile, request access.

Request a free trial

Janux Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on pr
Drug Discovery
La Jolla, CA
69 As of 2024

Wilmington, DE
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Janux Therapeutics Competitors (65)

One of Janux Therapeutics’s 65 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Lava Therapeutics Formerly VC-backed Utrecht, Netherlands
You’re viewing 5 of 65 competitors. Get the full list »

Janux Therapeutics Patents

Janux Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230357429-A1 Optimized antibodies targeting trop2 and uses thereof Pending 04-May-2022
US-20230357447-A1 Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof Pending 04-May-2022
US-20240059790-A1 Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens Pending 04-Apr-2022
AU-2023250347-A1 Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens Pending 04-Apr-2022
AU-2022272906-A9 Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens Pending 12-May-2021 A61K47/6849
To view Janux Therapeutics’s complete patent history, request access »

Janux Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Janux Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Janux Therapeutics‘s full profile, request access.

Request a free trial

Janux Therapeutics ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

28.75 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,035

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view Janux Therapeutics’s complete esg history, request access »

Janux Therapeutics FAQs

  • When was Janux Therapeutics founded?

    Janux Therapeutics was founded in 2017.

  • Where is Janux Therapeutics headquartered?

    Janux Therapeutics is headquartered in La Jolla, CA.

  • What is the size of Janux Therapeutics?

    Janux Therapeutics has 69 total employees.

  • What industry is Janux Therapeutics in?

    Janux Therapeutics’s primary industry is Drug Discovery.

  • Is Janux Therapeutics a private or public company?

    Janux Therapeutics is a Public company.

  • What is Janux Therapeutics’s stock symbol?

    The ticker symbol for Janux Therapeutics is JANX.

  • What is the current stock price of Janux Therapeutics?

    As of 13-Nov-2024 the stock price of Janux Therapeutics is $52.03.

  • What is the current market cap of Janux Therapeutics?

    The current market capitalization of Janux Therapeutics is $2.73B.

  • What is Janux Therapeutics’s current revenue?

    The trailing twelve month revenue for Janux Therapeutics is $13M.

  • Who are Janux Therapeutics’s competitors?

    Ayala Pharmaceuticals, CytomX Therapeutics, Kite Pharma, Inovio Pharmaceuticals, and Lava Therapeutics are some of the 65 competitors of Janux Therapeutics.

  • What is Janux Therapeutics’s annual earnings per share (EPS)?

    Janux Therapeutics’s EPS for 12 months was -$1.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »